Benny Vittrup Jensen

Summary

Affiliation: University of Copenhagen
Country: Denmark

Publications

  1. ncbi Extracellular matrix building marked by the N-terminal propeptide of procollagen type I reflect aggressiveness of recurrent breast cancer
    Benny Vittrup Jensen
    Department of Oncology, University Hospital of Herlev, Copenhagen, Denmark
    Int J Cancer 98:582-9. 2002
  2. ncbi [Drug therapy of patients with metastatic colorectal cancer]
    Per Pfeiffer
    Odense Universitetshospital, Onkologisk afdeling R
    Ugeskr Laeger 167:4261-5. 2005
  3. ncbi Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer
    Benny Vittrup Jensen
    Department of Oncology, University Hospital of Copenhagen, Herlev, Denmark
    Semin Oncol 33:S15-21. 2006
  4. ncbi Is YKL-40 a new therapeutic target in cancer?
    Julia S Johansen
    Herlev Hospital, University of Copenhagen, Department of Rheumatology Q107, Herlev Ringvej 75, DK 2730 Herlev, Denmark
    Expert Opin Ther Targets 11:219-34. 2007
  5. ncbi Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients
    B V Jensen
    Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark
    Ann Oncol 13:699-709. 2002
  6. ncbi High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer
    Benny Vittrup Jensen
    Department of Oncology, Herlev Hospital, Hvidovre Hospital, University of Copenhagen, DK 2750 Herlev Denmark
    Clin Cancer Res 9:4423-34. 2003
  7. doi Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab
    Kristin Skougaard
    Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark
    J Nucl Med 54:1026-31. 2013
  8. ncbi A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy
    Dorte Lisbet Nielsen
    Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark Electronic address
    Cancer Treat Rev 40:701-15. 2014
  9. doi Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer
    Camilla Qvortrup
    Department of Oncology, Odense University Hospital, Odense, Denmark
    Acta Oncol 49:833-6. 2010
  10. ncbi Serum YKL-40, a new prognostic biomarker in cancer patients?
    Julia S Johansen
    Department of Rheumatology Q107, Herlev Hospital, Herlev Ringvej 75, DK 2730 Herlev, Denmark
    Cancer Epidemiol Biomarkers Prev 15:194-202. 2006

Detail Information

Publications16

  1. ncbi Extracellular matrix building marked by the N-terminal propeptide of procollagen type I reflect aggressiveness of recurrent breast cancer
    Benny Vittrup Jensen
    Department of Oncology, University Hospital of Herlev, Copenhagen, Denmark
    Int J Cancer 98:582-9. 2002
    ..Serum PINP levels may be a diagnostic and prognostic tool that indicate breast cancer activity, aggressiveness, expansion and metastasis and a predictor of outcome after anthracycline-based chemotherapy...
  2. ncbi [Drug therapy of patients with metastatic colorectal cancer]
    Per Pfeiffer
    Odense Universitetshospital, Onkologisk afdeling R
    Ugeskr Laeger 167:4261-5. 2005
    ..Instead of being a more or less acute life-threatening disease, metastatic colorectal cancer may exist as a chronic condition for years...
  3. ncbi Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer
    Benny Vittrup Jensen
    Department of Oncology, University Hospital of Copenhagen, Herlev, Denmark
    Semin Oncol 33:S15-21. 2006
    ..Further investigation is required into the use of angiotensin-converting enzyme inhibitors to redress cardiac damage and new methods of identifying patients at high risk of congestive heart failure before cardiac damage has occurred...
  4. ncbi Is YKL-40 a new therapeutic target in cancer?
    Julia S Johansen
    Herlev Hospital, University of Copenhagen, Department of Rheumatology Q107, Herlev Ringvej 75, DK 2730 Herlev, Denmark
    Expert Opin Ther Targets 11:219-34. 2007
    ..Drugs inhibiting YKL-40 should be explored as new cancer therapeutics...
  5. ncbi Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients
    B V Jensen
    Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark
    Ann Oncol 13:699-709. 2002
    ..As no prospective studies in a larger series have been performed, these recommendations are based on retrospective data on small numbers of patients...
  6. ncbi High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer
    Benny Vittrup Jensen
    Department of Oncology, Herlev Hospital, Hvidovre Hospital, University of Copenhagen, DK 2750 Herlev Denmark
    Clin Cancer Res 9:4423-34. 2003
    ....
  7. doi Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab
    Kristin Skougaard
    Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark
    J Nucl Med 54:1026-31. 2013
    ....
  8. ncbi A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy
    Dorte Lisbet Nielsen
    Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark Electronic address
    Cancer Treat Rev 40:701-15. 2014
    ..Identification of predictive biomarkers and improvement of our understanding of molecular mechanisms is crucial...
  9. doi Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer
    Camilla Qvortrup
    Department of Oncology, Odense University Hospital, Odense, Denmark
    Acta Oncol 49:833-6. 2010
    ..Results of continuous sunitinib, in combination with cetuximab and irinotecan every other week (SIC) for compassionate use in heavily pre-treated patients with mCRC are presented...
  10. ncbi Serum YKL-40, a new prognostic biomarker in cancer patients?
    Julia S Johansen
    Department of Rheumatology Q107, Herlev Hospital, Herlev Ringvej 75, DK 2730 Herlev, Denmark
    Cancer Epidemiol Biomarkers Prev 15:194-202. 2006
    ....
  11. doi Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer
    Finn Ole Larsen
    Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark
    Acta Oncol 51:231-3. 2012
    ..The efficacy and safety of bevacizumab and capecitabine in heavily pre-treated patients with metastatic colorectal cancer were evaluated...
  12. doi Observer variability in a phase II trial - assessing consistency in RECIST application
    Kristin Skougaard
    Department of Oncology, Copenhagen University Hospital Herlev, Denmark
    Acta Oncol 51:774-80. 2012
    ..To assess the consistency of Response Evaluation Criteria in Solid Tumours (RECIST) application in a phase II trial...
  13. ncbi Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil
    Per Pfeiffer
    Department of Oncology, Odense University Hospital, Odense, Denmark
    Acta Oncol 46:697-701. 2007
    ..Salvage therapy with cetuximab and irinotecan is effective in patients pretreated with irinotecan, and oxaliplatin and in a general population the results from the BOND I study was confirmed...
  14. ncbi [Combined surgical and oncological management of colorectal liver metastases]
    Magnus Bergenfeldt
    Herlev Hospital, Afdelingen for Kirurgisk Gastroenterologi, Herlev
    Ugeskr Laeger 170:1353-6. 2008
    ..Bilateral, multiple and large metastases can also be treated by complex combinations of portal vein embolization/ligature, staged resections and local (radiofrequency) ablation...
  15. ncbi Re-treatment with cetuximab in patients with severe hypersensitivity reactions to cetuximab. Two case reports
    Dorte L Nielsen
    Acta Oncol 45:1137-8. 2006
  16. ncbi [Treatment of liver and lung metastases from colorectal cancer]
    Flemming Burcharth
    Amtssygehuset i Herlev, Kirurgisk gastroenterologisk afdeling
    Ugeskr Laeger 167:4268-72. 2005
    ....